Company profile CRSP
CRISPR Therapeutics AG
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad ran...ge of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Show More
After 34 days of this quarter the interest is at 218.0. Based on that we can calculate that during remaining 58 days it will total up to 590.0. crispr therapeutics -stock -share expected interest is significantly higher compared to previous quarter (+62.1%) and same quarter last year (+66.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 0 |
| 2019 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 364 inf% YoY inf% QoQ | 575 inf% YoY 58.0% QoQ |
| 2021 | 686 inf% YoY 19.3% QoQ | 519 inf% YoY -24.3% QoQ | 372 2.2% YoY -28.3% QoQ | 482 -16.2% YoY 29.6% QoQ |
| 2022 | 568 -17.2% YoY 17.8% QoQ | 460 -11.4% YoY -19.0% QoQ | 358 -3.8% YoY -22.2% QoQ | 355 -26.3% YoY -0.8% QoQ |
| 2023 | 443 -22.0% YoY 24.8% QoQ | 468 1.7% YoY 5.6% QoQ | 364 1.7% YoY -22.2% QoQ | 218 -38.6% YoY -40.1% QoQ |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of crispr therapeutics -stock -share was 23.97 per week. The last year interest of crispr therapeutics -stock -share compared to the last 5 years has changed by 38.97%. The interest for crispr therapeutics -stock -share is trending. This didn't exist 5 years ago.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for CRSP
Company name: CRISPR Therapeutics AG
Sector: Manufacturing
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-05-13T18:35:53Z
Analyst Upgrades
Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $562026-05-06T19:49:04Z
Analyst Upgrades
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $822026-05-06T12:30:00Z
GlobeNewswire
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference2026-05-04T20:30:00Z
GlobeNewswire
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results2026-04-07T12:00:00Z
GlobeNewswire
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference2026-03-30T13:15:00Z
GlobeNewswire
Legendary Investors are Rotating Capital into AI Powered Biotech2026-03-24T11:05:00-04:00
PR Newswire
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning2026-03-17T13:32:08Z
Analyst Upgrades
Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Raises Price Target to $1102026-03-10T11:00:00Z
GlobeNewswire
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering2026-02-25T09:00:00-05:00
PR Newswire
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 20262026-02-17T13:18:56Z
Analyst Upgrades
Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $762026-02-13T18:45:49Z
Analyst Upgrades
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens2026-02-13T16:17:31Z
Analyst Upgrades
TD Cowen Maintains Hold on CRISPR Therapeutics, Raises Price Target to $452026-02-13T16:01:02Z
Analyst Upgrades
Evercore ISI Group Maintains Outperform on CRISPR Therapeutics, Raises Price Target to $742026-02-13T11:32:46Z
Analyst Upgrades
Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82